Top ▲

polo like kinase 2

Click here for help

Target id: 2169

Nomenclature: polo like kinase 2

Abbreviated Name: PLK2

Family: Polo-like kinase (PLK) family

Contents:

Gene and Protein Information Click here for help
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human - 685 5q11.2 PLK2 polo like kinase 2
Mouse - 682 13 D2.1 Plk2 polo like kinase 2
Rat - 682 2q14 Plk2 polo-like kinase 2
Previous and Unofficial Names Click here for help
polo-like kinase 1 | serine/threonine-protein kinase SNK | serum-inducible kinase | polo-like kinase 2
Database Links Click here for help
Alphafold Q9NYY3 (Hs), P53351 (Mm), Q9R012 (Rn)
BRENDA 2.7.11.21
CATH/Gene3D 3.30.1120.30
ChEMBL Target CHEMBL5938 (Hs)
Ensembl Gene ENSG00000145632 (Hs), ENSMUSG00000021701 (Mm), ENSRNOG00000011951 (Rn)
Entrez Gene 10769 (Hs), 20620 (Mm), 83722 (Rn)
Human Protein Atlas ENSG00000145632 (Hs)
KEGG Enzyme 2.7.11.21
KEGG Gene hsa:10769 (Hs), mmu:20620 (Mm), rno:83722 (Rn)
OMIM 607023 (Hs)
Pharos Q9NYY3 (Hs)
RefSeq Nucleotide NM_001252226 (Hs), NM_152804 (Mm), NM_031821 (Rn)
RefSeq Protein NP_006613 (Hs), NP_690017 (Mm), NP_114009 (Rn)
SynPHARM 81116 (in complex with BI-2536)
UniProtKB Q9NYY3 (Hs), P53351 (Mm), Q9R012 (Rn)
Wikipedia PLK2 (Hs)
Enzyme Reaction Click here for help
EC Number: 2.7.11.21

Download all structure-activity data for this target as a CSV file go icon to follow link

Inhibitors
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
BI-2536 Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 8.5 pIC50 6
⤷ pIC50 8.5 (IC50 3.5x10-9 M) [6]
rucaparib metabolite M324 Small molecule or natural product Click here for species-specific activity table Hs Inhibition 6.2 pIC50 5
⤷ pIC50 6.2 (IC50 5.91x10-7 M) [5]
onvansertib Small molecule or natural product Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition <5.0 pIC50 2
⤷ pIC50 <5.0 (IC50 >1x10-5 M) [2]
DiscoveRx KINOMEscan® screen Click here for help
A screen of 72 inhibitors against 456 human kinases. Quantitative data were derived using DiscoveRx KINOMEscan® platform.
http://www.discoverx.com/services/drug-discovery-development-services/kinase-profiling/kinomescan
Reference: 3,7
Key to terms and symbols Click column headers to sort
Target used in screen: PLK2
Ligand Sp. Type Action Value Parameter
BI-2536 Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 9.1 pKd
tamatinib Small molecule or natural product Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibitor Inhibition 7.5 pKd
staurosporine Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 6.7 pKd
lestaurtinib Small molecule or natural product Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibitor Inhibition 6.5 pKd
GSK-461364A Small molecule or natural product Hs Inhibitor Inhibition 6.3 pKd
dovitinib Small molecule or natural product Hs Inhibitor Inhibition 6.2 pKd
bosutinib Small molecule or natural product Approved drug Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibitor Inhibition 6.0 pKd
NVP-TAE684 Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 5.9 pKd
PP-242 Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 5.8 pKd
ruxolitinib Small molecule or natural product Approved drug Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibitor Inhibition 5.8 pKd
Displaying the top 10 most potent ligands  View all ligands in screen »
EMD Millipore KinaseProfilerTM screen/Reaction Biology Kinase HotspotSM screen Click here for help
A screen profiling 158 kinase inhibitors (Calbiochem Protein Kinase Inhibitor Library I and II, catalogue numbers 539744 and 539745) for their inhibitory activity at 1µM and 10µM against 234 human recombinant kinases using the EMD Millipore KinaseProfilerTM service.

A screen profiling the inhibitory activity of 178 commercially available kinase inhibitors at 0.5µM against a panel of 300 recombinant protein kinases using the Reaction Biology Corporation Kinase HotspotSM platform.

http://www.millipore.com/techpublications/tech1/pf3036
http://www.reactionbiology.com/webapps/main/pages/kinase.aspx

Reference: 1,4
Key to terms and symbols Click column headers to sort
Target used in screen: Snk/PLK2
Ligand Sp. Type Action % Activity remaining at 0.5µM % Activity remaining at 1µM % Activity remaining at 10µM
PDK1/Akt/Flt dual pathway inhibitor Small molecule or natural product Hs Inhibitor Inhibition 37.3 73.0 34.0
casein kinase II inhibitor III Small molecule or natural product Hs Inhibitor Inhibition 51.5 39.0 25.0
wortmannin Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 51.6
SB 218078 Small molecule or natural product Hs Inhibitor Inhibition 62.4 105.0 80.0
isogranulatimide Small molecule or natural product Hs Inhibitor Inhibition 63.8 38.0 38.0
PKR inhibitor Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 78.7 49.0 17.0
fascaplysin Small molecule or natural product Hs Inhibitor Inhibition 79.9 95.0 101.0
aloisine A Small molecule or natural product Hs Inhibitor Inhibition 83.9 100.0 86.0
KU-55933 Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 84.6 93.0 96.0
Cdk1/2 inhibitor III Small molecule or natural product Ligand has a PDB structure Hs Inhibitor Inhibition 88.5 71.0 26.0
Displaying the top 10 most potent ligands  View all ligands in screen »

References

Show »

1. Anastassiadis T, Deacon SW, Devarajan K, Ma H, Peterson JR. (2011) Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat Biotechnol, 29 (11): 1039-45. [PMID:22037377]

2. Beria I, Bossi RT, Brasca MG, Caruso M, Ceccarelli W, Fachin G, Fasolini M, Forte B, Fiorentini F, Pesenti E et al.. (2011) NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor. Bioorg Med Chem Lett, 21 (10): 2969-74. [PMID:21470862]

3. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK, Zarrinkar PP. (2011) Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol, 29 (11): 1046-51. [PMID:22037378]

4. Gao Y, Davies SP, Augustin M, Woodward A, Patel UA, Kovelman R, Harvey KJ. (2013) A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. Biochem J, 451 (2): 313-28. [PMID:23398362]

5. Hu H, Serra C, Zhang W, Scrivo A, Fernández-Carasa I, Consiglio A, Aytes A, Pujana MA, Llebaria A, Antolin AA. (2024) Identification of differential biological activity and synergy between the PARP inhibitor rucaparib and its major metabolite. Cell Chem Biol, 31 (5): 973-988.e4. [PMID:38335967]

6. Steegmaier M, Hoffmann M, Baum A, Lénárt P, Petronczki M, Krssák M, Gürtler U, Garin-Chesa P, Lieb S, Quant J et al.. (2007) BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol, 17 (4): 316-22. [PMID:17291758]

7. Wodicka LM, Ciceri P, Davis MI, Hunt JP, Floyd M, Salerno S, Hua XH, Ford JM, Armstrong RC, Zarrinkar PP et al.. (2010) Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry. Chem Biol, 17 (11): 1241-9. [PMID:21095574]

How to cite this page

Polo-like kinase (PLK) family: polo like kinase 2. Last modified on 12/02/2024. Accessed on 25/04/2025. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetomalariapharmacology.org/GRAC/ObjectDisplayForward?objectId=2169.